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http:WHAT THIS PAPER ADDS
ABO blood type is a major determinant of the risk of atherothrombotic events in the general population. This is
the ﬁrst study to assess the prognostic implications of ABO blood type in vascular surgery patients. ABO blood
type did not inﬂuence the risk of perioperative cardiovascular complications and long-term mortality in vascular
surgery patients.Objectives: Thrombotic complications are common in vascular surgery patients. Non-O blood types are
associated with an increased risk of thrombo-embolic diseases. The aim of this study is to assess the prognostic
implications of non-O vs. O blood type regarding 30-day cardiovascular events and long-term mortality after
vascular surgery.
Methods: The population of this retrospective cohort study consisted of 4679 patients undergoing elective major
vascular surgery between the years 1990 and 2011. Baseline characteristics, ABO blood type and follow-up were
obtained. Multivariable regression analyses, adjusted for age, gender, medical history, medication and smoking
were used to evaluate the impact of non-O blood type on 30-day cardiovascular events (cardiovascular death,
myocardial infarction and stroke) and long-term mortality.
Results: Non-O blood type was present in 2627 (56%) patients. Within 30 days after surgery, 129 (4.9%) non-O
and 112 (5.5%) O patients suffered a cardiovascular event (P ¼ 0.42). Non-O blood type was not associated with
increased mortality during long-term follow-up (adjusted hazard ratio (aHR) 0.96; 95% conﬁdence interval (CI)
0.88e1.04, with a median follow-up of 4 years). Anti-platelet and anticoagulant drugs did not interact with the
relationship between ABO blood type and long-term outcome.
Conclusion: Non-O blood type is not associated with either 30-day cardiovascular complications or long-term
mortality in vascular surgery patients.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Article history: Received 22 May 2012, Accepted 15 November 2012, Available online 8 January 2013
Keywords: ABO blood-group system, Vascular surgical procedures, Cardiovascular complications, MortalityAtherosclerosis is a systemic disease that affects multiple
organ systems.1 Patients with peripheral arterial disease
commonly suffer from concomitant coronary artery disease
or cerebrovascular disease.1,2 These patients are therefore
at increased risk for both perioperative and long-term
cardiovascular events, including stroke and myocardial
infarction.3,4 Arterial thrombosis is responsible for the
majority of these, both in the perioperative and the non-
surgical setting.5
Several studies reported an increased risk of thrombotic
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//dx.doi.org/10.1016/j.ejvs.2012.11.022peripheral arterial disease and venous thrombo-embolism,
in people with non-O blood types in the general pop-
ulation.6e10
It is unclear whether or not ABO blood type inﬂuences
outcome after vascular surgery. We conducted the current
study to evaluate the effect of ABO blood type on both
perioperative cardiovascular complications and long-term
survival after vascular surgery.
MATERIALS AND METHODS
This retrospective, single-centre study comprised a pop-
ulation of 4679 patients, referred for elective major vascular
surgery, including abdominal aortic, carotid artery and
lower limb arterial repair. All patients underwent surgery
between 1990 and 2011. The study was conducted in
accordance with the Declaration of Helsinki and was
approved by the Institutional Review Board of the Erasmus
Medical Center.
E.J. Bakker et al. 257The obtained medical history included risk factors
according to the Revised Cardiac Risk Index: ischaemic heart
disease (history of angina pectoris, myocardial infarction or
coronary revascularisation), heart failure (clinical signs
according to the New York Heart Association, previous
hospitalisation for decompensated heart failure), cerebro-
vascular disease (history of transient ischaemic attack or
ischaemic or haemorrhagic stroke), renal dysfunction
(serum creatinin >2 mg/dl) and diabetes mellitus (fasting
blood glucose 7.0 mmol l1 or insulin or oral anti-diabetic
drug use). Further, age, sex, smoking status, hypertension
(systolic blood pressure >140 mmHg or diastolic
>90 mmHg in non-diabetics, systolic blood pressure
>130 mmHg or diastolic blood pressure >80 mmHg in
diabetics or use of anti-hypertensive medication) and
chronic obstructive pulmonary disease were recorded, as
well as medication use, with focus on anti-platelet and
anticoagulant drugs. Open abdominal aortic repair and
open lower limb revascularisation were categorised as high-
risk procedures, all other procedures as intermediate risk.
Per hospital protocol, chronic aspirin therapy is routinely
continued perioperatively. The decision whether or not to
interrupt vitamin K antagonist therapy and whether or not
to initiate bridging therapy with heparin or low-molecular-
weight heparin (LMWH) was made on a case-to-case basis.
Per hospital protocol, thromboprophylaxis is routinely
initiated the night prior to surgery using prophylactic doses
of LMWH in patients not receiving therapeutic doses of
LMWH or oral anticoagulants. LMWH is continued until
discharge from the hospital.
Study ‘end’ points were 30-day cardiovascular events,
including cardiovascular mortality, non-fatal myocardial
infarction and cerebrovascular events, and 30-day and long-
term all-cause mortality. Myocardial infarction was deﬁned
as the presence of biochemical evidence of myocardial
necrosis (the typical rise and fall of either cardiac Troponin T
with at least one measurement >0.03 ng ml1 or of crea-
tine kinase with an MB fraction of >10%) combined with
characteristic symptoms or electrocardiographic signs of
ischaemia (new-onset ST-T changes or left bundle branch
block or development of pathological Q-waves). Cause of
death within 30 days after surgery was obtained from
hospital records and was classiﬁed as either cardiovascular
or non-cardiovascular death. Cardiovascular death was
deﬁned as any death with a cerebro-cardiovascular
complication as primary or secondary cause, including
death following myocardial infarction, cardiac arrhythmias,
congestive heart failure, stroke and surgery-related bleeding
complications. Sudden unexpected death was also classiﬁed
as a cardiovascular death.
All data were tabulated according to O and non-O blood
type. Categorical variables are described as numbers and
percentages. Continuous variables were described as
means  standard deviation. Duration of follow-up was
described as median with interquartile range (IQR). Categor-
ical data were compared using a chi-squared test. Continuous
data were compared using analysis of variance (ANOVA).
Cumulative long-term survival was determined using theKaplaneMeier method and the log-rank test. Logistic
regression analysis was performed to evaluate the effect of
non-O blood type on 30-day cardiovascular events. Cox
regression analysis was performed to assess the effect of non-
O blood type on long-term survival. Subgroup analysis was
performed for age (>65 and <65 years), gender, statin use
and anti-platelet/anticoagulant medication use. Multivariate
regression analyses were adjusted for high-risk type of
surgery, gender, age, hypertension, diabetesmellitus, smoking
status, renal failure, ischaemic heart disease, hyper-
cholesterolaemia, congestive heart failure, cerebrovascular
disease, chronic obstructive pulmonary disease and the use of
beta-blockers, statins and anti-platelet and anticoagulant
drugs.We reported crude and adjusted odds ratios (ORs) and
hazard ratios (HRs) and their 95% conﬁdence intervals (CIs).
For all tests, a P< 0.05 (two-sided)was considered signiﬁcant.
All analyses were performed using PASW version 17.0 statis-
tical software (SPSS Inc., Chicago, IL, USA).RESULTS
The study population consisted of 4679 consecutive patients
who underwent elective vascular surgery. Abdominal aortic
repair was performed in 1814 (39%) patients, lower
extremity revascularisation in 1834 (39%) patients and
carotid surgery in 1027 (22%) patients, respectively. The
median follow-up was 4 (IQR 2e8) years. The majority of
patients were men (73%) and the mean age was 66  12
years. Non-O blood type was present in 2627 (56%) patients.
Of all patients, 52% had no or one risk factor, 31% had two
risk factors and 17% had three or more risk factors according
to the Revised Cardiac Risk Index. O and non-O groups
differed signiﬁcantly regarding male gender (74% vs. 72%,
P ¼ 0.04), ischaemic heart disease (34% vs. 37%, P ¼ 0.02)
and aspirin use (48% vs. 45%, P ¼ 0.04). There were no
signiﬁcant differences between O and non-O groups
regarding other co-morbidities, medication use, age and
surgical characteristics, as demonstrated in Table 1.
During 30-day follow-up 241 (5.2%) patients had
a cardiovascular event, including 132 (2.8%) cardiovascular
deaths, 66 (1.4%) non-fatal myocardial infarctions and 36
(0.8%) non-fatal strokes, as presented in Table 2. No
signiﬁcant differences between O and non-O blood types
were observed regarding stroke (1.0% vs. 0.6%, P ¼ 0.09),
non-fatal myocardial infarction (1.5% vs. 1.4%, P ¼ 0.51),
cardiovascular death (2.8% vs. 2.8%, P ¼ 1.00) and
cardiovascular events (5.5% vs. 4.9%, P ¼ 0.42). Within 30
days of surgery, 228 patients died of any cause. No signiﬁ-
cant difference was observed between O and non-O blood
type (4.9% vs. 4.8%, P ¼ 0.89). Multivariate analyses
demonstrated that non-O blood type was not associated
with 30-day cardiovascular events (OR 0.87, 95% CI 0.67e
1.13, P ¼ 0.32).
During long-term follow-up 1233 (47%) patients with
non-O blood type died, compared with 981 (48%) patients
with O blood type (P ¼ 0.60). Cumulative survival for all
patients is shown in Fig. 1 (log rank P ¼ 0.88). In a multi-
variate model, non-O blood type was not associated with
Table 1. Baseline characteristics according to blood type.
O
(n ¼ 2052)
Non-O
(n ¼ 2627)
P-value
Demographics
Mean age (SD) 67 (11) 66 (11) 0.23
Mean BMI (SD) 26 (4) 26 (4) 0.28
Male gender (%) 1527 (74) 1884 (72) 0.04
Surgery type
Carotid surgery 470 (23) 557 (21)
Abdominal aortic surgery 810 (40) 1004 (38) 0.09
Peripheral arterial surgery 769 (38) 1065 (41)
Medical history (%)
Congestive heart failure 122 (6) 178 (7) 0.25
Cerebrovascular disease 648 (32) 766 (29) 0.08
Hypertension 985 (48) 1188 (45) 0.06
Diabetes mellitus 366 (18) 463 (18) 0.88
Current smoking 663 (32) 863 (33) 0.71
Creatinin >2 mg/dL 190 (9) 270 (10) 0.26
Ischaemic heart disease 690 (34) 973 (37) 0.02
COPD 800 (39) 1018 (39) 0.88
Revised Cardiac Risk Index
Cardiac risk factors (SD) 1.6 (1.0) 1.6 (1.0) 0.28
Medication use (%)
Aspirin 979 (48) 1175 (45) 0.04
Anticoagulants 686 (33) 904 (34) 0.49
Beta-blockers 949 (46) 1173 (45) 0.29
Statins 770 (38) 965 (37) 0.58
Abbreviations: COPD: chronic obstructive pulmonary disease.
Figure 1. Kaplan Meier estimates for long-term all-cause mortality,
stratiﬁed according O and non-O blood type.
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formed several subgroup analyses and found no interaction
between the association between ABO blood type and long-
term mortality by age, gender, surgical procedure and anti-
thrombotic medication use (Fig. 2).DISCUSSION
The current study demonstrated that non-O blood type
was not associated with an increased prevalence of either
30-day cardiovascular events or long-term mortality, asTable 2. 30-day outcome according to blood type.
N (%) Univariab
OR
Stroke
O blood type 24/2052 (1.2) Ref
Non-O blood type 17/2627 (0.6) 0.55
Myocardial infarction
O blood type 38/2052 (1.9) Ref
Non-O blood type 47/2627 (1.8) 0.87
Cardiovascular death
O blood type 58/2052 (2.8) Ref
Non-O blood type 74/2627 (2.8) 0.99
Cardiovascular events
O blood type 112/2052 (5.5) Ref
Non-O blood type 129/2627 (4.9) 0.90
All-cause mortality
O blood type 101/2052 (4.9) Ref
Non-O blood type 127/2627 (4.8) 0.98compared with O blood type. After adjusting for cardio-
vascular risk factors, age, gender, smoking and medication
use, the ORs for 30-day cardiovascular events and HR for
long-term mortality were 0.87 (95% CI 0.67e1.13) and 0.96
(95% CI 0.88e1.04).
Von Willebrand factor is an important factor in haemo-
stasis. It mediates platelet adherence to the sub-
endothelium in vascular injury and serves as a carrier
protein of clotting factor VIII, increasing plasma half-life of
clotting factor VIII from 2 to 12 h.12,13 Increased levels of
von Willebrand factor are associated with an increased risk
of both arterial and venous thrombosis.14e18
A major determinant of the circulating von Willebrand
factor level is ABO blood type. In individuals with non-O
blood types, the plasma levels of von Willebrand factor are
elevated by 25e30%, as compared with individuals with O
blood type.11,19 The mechanism through which ABO blood
type inﬂuences plasma levels of von Willebrand factor is notle Multivariable
(95% CI) OR (95% CI)
Ref
(0.29e1.03) 0.56 (0.30e1.05)
Ref
(0.63e1.49) 0.96 (0.61e1.50)
Ref
(0.70e1.41) 0.91 (0.64e1.30)
Ref
(0.69e1.16) 0.87 (0.67e1.13)
Ref
(0.75e1.28) 0.91 (0.69e1.20)
Figure 2. Non-O blood types and long-term mortality hazard in
subgroups.
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antigens on the surface of large, highly thrombogenic von
Willebrand particles inhibit proteolysis into smaller, less
thrombogenic particles by the enzyme ADAMTS13, effec-
tively decreasing von Willebrand factor clearance.20,21
Clotting factor VIII levels are consequently higher in indi-
viduals with non-O blood types.
In the general population, non-O blood type has been
linked to an increased risk of peripheral arterial disease,
myocardial infarction, ischaemic stroke and venous
thrombo-embolism, with ORs of 1.45, 1.25, 1.14 and 1.79,
respectively.6e10
Peripheral arterial disease patients are at increased risk
of cardiovascular events, in both the perioperative and the
non-surgical setting, most importantly myocardial infarc-
tion.22 Thrombotic arterial occlusion at the site of
a ruptured atherosclerotic plaque is responsible for most of
these events.5 Chronic aspirin therapy is recommended for
peripheral arterial disease patients to prevent peripheral,
cerebral and myocardial thrombotic complications.23
To our knowledge, no data were available on the effect of
ABO blood type on cardiovascular events and prognosis in
peripheral arterial disease patients. In the current study, we
found no evidence of such relationships. These ﬁndings are
comparable to the results reported by Ketch et al., who
reported no difference in 1-year mortality between non-O
and O blood type in a cohort of 1198 patients who
underwent a percutaneous coronary intervention for acute
myocardial infarction (HR 0.89; 95% CI 0.63e1.25).24 In
contrast, Carpeggiani et al. reported an increased long-term
mortality in patients with non-O blood type in a cohort
consisting of 4901 patients hospitalised for coronary artery
disease, with a HR of 1.24 (95% CI: 1.01e1.52).25 Their
results were driven mainly by a strong relation found in
women under the age of 65 (HR 4.61; 95% CI 1.93e11.00).
In a subanalysis of women under 65, we found no signiﬁ-
cantly increased long-term mortality for non-O blood types
(HR 0.95; 95% CI 0.69e1.30).The association between ABO blood type and throm-
botic events, as seen in the general population, might be
inﬂuenced by the use of anti-platelet and anticoagulant
medication. In a cohort of 661 patients with unprovoked
venous thrombo-embolism, being treated with vitamin K
antagonists, elevated clotting factor VIII levels were not
associated with the risk of recurrent venous thrombo-
embolism (0.7% per patient year, as compared with 1.1%
per patient year in patients without thrombophilia).26 In
the study by Ketch in myocardial infarction patients,
routinely treated with anti-platelet therapy, the rate of
recurrent thrombotic events (myocardial infarction, stent
thrombosis and target vessel revascularisation) was similar
in patients with non-O and O blood types.24 In our study,
the prognostic implications of ABO blood type after
vascular surgery were similar in patients using anti-platelet
drugs, anticoagulant drugs, both or neither. The routine
administration of perioperative thromboprophylaxis might
have inﬂuenced the relationship between ABO blood type
and perioperative events.
Another factor potentially inﬂuencing the relationship
between ABO blood type and thrombotic events is the use
of statins. Jaumdally et al. describe a decline in serum von
Willebrand factor levels after intensifying of statin therapy
(atorvastatin 80 mg daily).27 Statin use did not inﬂuence the
prognostic implications of ABO blood type in our study.
In the general population, non-O blood types lead to an
increased risk of peripheral arterial disease, myocardial
infarction and stroke. However, non-O blood type seems
not to be associated with outcome in patients after vascular
surgery (current study) and myocardial infarction.24 ‘Index
event bias’ may attribute to this paradox, as all patients are
selected based on an index atherothrombotic event (the
requirement of vascular surgery).28
We assessed only the phenotype and not genotype of the
ABO blood group. The highest levels of clotting factor VIII
and von Willebrand factor are observed in A1A/A1B/BB,
intermediate levels in A1O/BO and the lowest levels in OO
genotype.29 Possibly, by comparing O to non-O instead of
A1A/A1B/BB to OO, the effects of ABO on prognosis were
diluted.
Although vascular surgery patients are considered to be
at relatively low risk of venous thrombo-embolism, it would
be interesting to assess the effects of ABO blood type on
the risk of postoperative venous thrombo-embolism in our
population.30 Unfortunately, due to the retrospective study
design, we were not able to systematically assess the
presence of postoperative deep venous thrombosis and
pulmonary embolism.
In conclusion, non-O blood type is not associated with
increased incidence of 30-day cardiovascular events or long-
term mortality after vascular surgery in our population.ACKNOWLEDGEMENTS
Bakker, Valentijn and van de Luijtgaarden are supported
with an unrestricted research grant from the Dutch foun-
dation ‘Lijf en leven’.
260 European Journal of Vascular and Endovascular Surgery Volume 45 Issue 3 March/2013CONFLICT OF INTEREST/FUNDING
None.
REFERENCES
1 van Kuijk JP, Flu WJ, Welten GM, Hoeks SE, Chonchol M,
Vidakovic R, et al. Long-term prognosis of patients with
peripheral arterial disease with or without polyvascular
atherosclerotic disease. Eur Heart J 2010;31:992e9.
2 Hertzer NR, Beven EG, Young JR, O’Hara PJ, Ruschhaupt 3rd WF,
Graor RA, et al. Coronary artery disease in peripheral vascular
patients. A classiﬁcation of 1000 coronary angiograms and
results of surgical management. Ann Surg 1984;199:223e33.
3 Welten GM, Schouten O, Hoeks SE, Chonchol M, Vidakovic R,
van Domburg RT, et al. Long-term prognosis of patients with
peripheral arterial disease: a comparison in patients with
coronary artery disease. J Am Coll Cardiol 2008;51:1588e96.
4 Back MR, Leo F, Cuthbertson D, Johnson BL, Shamesmd ML,
Bandyk DF. Long-term survival after vascular surgery: speciﬁc
inﬂuence of cardiac factors and implications for preoperative
evaluation. J Vasc Surg 2004;40:752e60.
5 Dawood MM, Gutpa DK, Southern J, Walia A, Atkinson JB,
Eagle KA. Pathology of fatal perioperative myocardial infarc-
tion: implications regarding pathophysiology and prevention.
Int J Cardiol 1996;57:37e44.
6 Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups
and vascular disease: a systematic review and meta-analysis.
J Thromb Haemost 2008;6:62e9.
7 Bronte-Stewart B, Botha MC, Krut LH. ABO blood groups in
relation to ischaemic heart disease. Br Med J 1962;1:1646e50.
8 Kingsbury KJ. Relation of ABO blood-groups to atherosclerosis.
Lancet 1971;1:199e203.
9 Ionescu DA, Marcu I, Bicescu E. Cerebral thrombosis, cere-
bral haemorrhage, and ABO blood-groups. Lancet 1976;1:
278e80.
10 Talbot S, Wakley EJ, Ryrie D, Langman MJ. ABO blood groups
and venous thromboembolic disease. Lancet 1970;1:1257e9.
11 Souto JC, Almasy L, Muniz-Diaz E, Soria JM, Borrell M, Bayen L,
et al. Functional effects of the ABO locus polymorphism on
plasma levels of von Willebrand factor, factor VIII, and acti-
vated partial thromboplastin time. Arterioscler Thromb Vasc
Biol 2000;20:2024e8.
12 Denis C, Baruch D, Kielty CM, Ajzenberg N, Christophe O,
Meyer D. Localization of von Willebrand factor binding
domains to endothelial extracellular matrix and to type VI
collagen. Arterioscler Thromb 1993;13:398e406.
13 Tuddenham EG, Lane RS, Rotblat F, Johnson AJ, Snape TJ,
Middleton S, et al. Response to infusions of polyelectrolyte
fractionated human factor VIII concentrate in human haemo-
philia A and von Willebrand’s disease. Br J Haematol 1982;52:
259e67.
14 Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR.
Role of clotting factor VIII in effect of von Willebrand factor on
occurrence of deep-vein thrombosis. Lancet 1995;345:152e5.
15 Nossent AY, van Marion V, van Tilburg NH, Rosendaal FR,
Bertina RM, van Mourik JA, et al. von Willebrand factor and its
propeptide: the inﬂuence of secretion and clearance on protein
levels and the risk of venous thrombosis. J Thromb Haemost
2006;4:2556e62.
16 Kraaijenhagen RA, in’t Anker PS, Koopman MM, Reitsma PH,
Prins MH, van den Ende A, et al. High plasma concentration of
factor VIIIc is a major risk factor for venous thromboembolism.
Thromb Haemost 2000;83:5e9.17 Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A,
Witteman JC, de Maat MP, et al. High von Willebrand factor
levels increase the risk of stroke: the Rotterdam study. Stroke
2010;41:2151e6.
18 van Schie MC, van Loon JE, de Maat MP, Leebeek FW. Genetic
determinants of von Willebrand factor levels and activity in
relation to the risk of cardiovascular disease: a review.
J Thromb Haemost 2011;9:899e908.
19 Shima M, Fujimura Y, Nishiyama T, Tsujiuchi T, Narita N,
Matsui T, et al. ABO blood group genotype and plasma von
Willebrand factor in normal individuals. Vox Sang 1995;68:
236e40.
20 Bowen DJ. An inﬂuence of ABO blood group on the rate of
proteolysis of von Willebrand factor by ADAMTS13. J Thromb
Haemost 2003;1:33e40.
21 Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, Haan E,
Kruitwagen CL, Sixma JJ, et al. The half-life of infused factor VIII
is shorter in hemophiliac patients with blood group O than in
those with blood group A. Thromb Haemost 2000;83:65e9.
22 Poldermans D, Bax JJ, Boersma E, De Hert S, Eeckhout E,
Fowkes G, et al. Guidelines for pre-operative cardiac risk
assessment and perioperative cardiac management in non-
cardiac surgery. Eur Heart J 2009;30:2769e812.
23 Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA,
Halperin JL, et al. ACC/AHA 2005 practice guidelines for the
management of patients with peripheral arterial disease (lower
extremity, renal, mesenteric, and abdominal aortic): a collabo-
rative report from the American Association for Vascular
Surgery/Society for Vascular Surgery, Society for Cardiovascular
Angiography and Interventions, Society for Vascular Medicine
and Biology, Society of Interventional Radiology, and the ACC/
AHA Task Force on Practice Guidelines (Writing Committee to
develop guidelines for the management of patients with
peripheral arterial disease): endorsed by the American Asso-
ciation of Cardiovascular and Pulmonary Rehabilitation;
National Heart, Lung, and Blood Institute; Society for Vascular
Nursing; TransAtlantic Inter-Society Consensus; and Vascular
Disease Foundation. Circulation 2006;113:e463e654.
24 Ketch TR, Turner SJ, Sacrinty MT, Lingle KC, Applegate RJ,
Kutcher MA, et al. ABO blood types: inﬂuence on infarct size,
procedural characteristics and prognosis. Thromb Res
2008;123:200e5.
25 Carpeggiani C, Coceani M, Landi P,Michelassi C, L’Abbate A. ABO
blood group alleles: a risk factor for coronary artery disease. An
angiographic study. Atherosclerosis 2010;211:461e6.
26 Kearon C, Julian JA, Kovacs MJ, Anderson DR, Wells P,
Mackinnon B, et al. Inﬂuence of thrombophilia on risk of
recurrent venous thromboembolism while on warfarin: results
from a randomized trial. Blood 2008;112:4432e6.
27 Jaumdally RJ, Lip GY, Varma C, Blann AD. Impact of high dose
atorvastatin on endothelial, platelet, and angiogenic indices:
effect of ethnicity, cardiovascular disease, and diabetes. Angi-
ology 2011;62:571e8.
28 Dahabreh IJ, Kent DM. Index event bias as an explanation for
the paradoxes of recurrence risk research. J Am Med Assoc
2011;305:822e3.
29 Jenkins PV, O’Donnell JS. ABO blood group determines plasma
von Willebrand factor levels: a biologic function after all?
Transfusion 2006;46:1836e44.
30 Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM,
Lassen MR, et al. Prevention of venous thromboembolism:
American College of Chest Physicians evidence-based clinical
practice guidelines (8th edition). Chest 2008;133:381Se453S.
